| Patent application number | Description | Published |
|---|
| 20080300222 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization - The invention provides novel phosphoantigen salts and novel crystalline phases of phosphoantigens salts, that the latter including non-solvated polymorphs, and solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, novel phosphoantigen crystalline phases. Methods of using such compositions for the treatment of disease, immunostimulatory or immune response modifying use are also provided. The invention also provides method for obtaining phosphoantigen crystals as well as highly pure phosphoantigen compositions. | 12-04-2008 |
| 20090069434 | Cystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Crystalline form VI of the compound of formula (I): | 03-12-2009 |
| 20090186934 | Beta Crystalline form of the Arginine Salt of Perindopril, a Process for its Preparation and Pharmaceutical Compositions Containing it. - β-crystalline form of the compound of formula (I): | 07-23-2009 |
| 20100036165 | Process for obtaining the crystalline form V of agomelatine - Process for obtaining the crystalline form V of the compound of formula (I): | 02-11-2010 |
| 20100063158 | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Crystalline form III of the compound of formula (I): | 03-11-2010 |
| 20100076088 | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Crystalline form IV of the compound of formula (I): | 03-25-2010 |
| 20110060002 | CONGLOMERATES OF TENATOPRAZOLE POTASSIUM SALTS - The invention relates to conglomerates of tenatoprazole potassium salts of the following general formula (I), that consist of an equimolar mixture of enantiomers having R and S configurations and capable of crystallisation in the form of a conglomerate, wherein said salts are selected from tenatoprazole dehydrated potassium salt, tenatoprazole potassium dimethanolate, tenatoprazole potassium diethanolate and tenatoprazole potassium ethylene-glycolate. The invention also relates to a pharmaceutical composition containing such salt, and to the use of said salt. | 03-10-2011 |
| Patent application number | Description | Published |
|---|
| 20090281192 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.38, 8.58, 7.34, 5.00 and 4.09 Å, and a process for the preparation thereof. | 11-12-2009 |
| 20090281193 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 9.45, 7.15, 5.13, 4.15 and 3.67 Å, and a process for the preparation thereof. | 11-12-2009 |
| 20100022653 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å, and a process for the preparation thereof. | 01-28-2010 |
| 20100048718 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 5.23, 5.03, 4.22 and 4.10 Å, and a process for the preparation thereof. | 02-25-2010 |
| 20100048719 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.31, 8.54, 7.27 and 3.62 Å, and a process for the preparation thereof. | 02-25-2010 |
